|
Treatment
|
n
|
Inhibition (%)*
|
Doubling time (days)**
|
Absolute growth delay (days)***
|
Normalized growth delay (days)
|
Enhancement factor
|
|---|
|
Control
|
5
| |
10.8 ± 1.2
| | | |
|
Ber5
|
5
|
27.6 ± 6.3
|
12.3 ± 2.5
|
1.5(12.3-10.8)
| | |
|
Ber10
|
5
|
58.1 ± 8.6
|
13.1 ± 3.0
|
2.3(13.1-10.8)
| | |
|
IR
|
5
|
37.8 ± 6.9
|
16.5 ± 1.5
|
5.7(16.5-10.8)
| | |
|
IR + Ber5
|
5
|
66.6 ± 9.2
|
21.4 ± 0.7
|
10.6(21.4-10.8)
|
9.1(10.6-1.5)
|
1.6(9.1/5.7)
|
|
IR + Ber10
|
5
|
75.9 ± 5.9
|
22.7 ± 4.6
|
11.9(22.7-10.8)
|
9.6(11.9-2.3)
|
1.7(9.6/5.7)
|
- *Tumor growth inhibition rate was calculated based on the tumor volume on Day 40.
- **Absolute growth delay: The doubling tumor time of treatment group minus that of control group;
- ***Normalized growth delay: The time of absolute growth delay of tumor in IR combined with Ber group minus that of Ber group.
